Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

OPERANDI project aims to address unmet clinical needs in the current management of advanced-stage HCC treated with TARE by exploring new opportunities provided by imaging-based artificial intelligence (AI) and data augmentation, simultaneous PET-MRI imaging, and novel approaches to increase patient selection and TARE efficacy (genomic profiling, radiopotentiators, and new radionuclides). The research aim to identify predictive and early markers indicative of TARE effectiveness based on a large prospective cohort of HCC patients. This cohort will be used to uncover relevant predictive signature

Trial Details

NCT ID
NCT06334965
Phase
NA
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Simultaneous 18F-Choline PET-MRI
Locations (sample)
  • Clichy, France|48.90018,2.30952
  • Clichy, France|48.90018,2.30952
  • Nantes, France|47.21725,-1.55336
  • Nantes, France|47.21725,-1.55336
  • Paris, France|48.85341,2.3488

Key Eligibility Criteria

  • Patients with HCC for whom TARE decision was made at the MDT
  • Patients ≥ 18 years of age
  • Diagnosis of HCC based on imaging (EASL guidelines) and confirmed histologically
  • At least one target lesion to be treated by radioembolisation, naïve to any previous treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →